12:00 AM
 | 
Jan 07, 2016
 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: c-jun N-terminal kinase (JNK); caspase recruitment domain family member 11 (CARD11)

Cancer

INDICATION: B cell lymphoma

Mouse and patient sample studies suggest JNK inhibitors could help treat a subtype of diffuse large B-cell lymphoma (DLBCL). Gain-of-function mutations in CARD11 are associated with poor outcomes in the active B cell-like subtype of DLBCL (ABC-DLBCL). In transgenic mice, expression of a human gain-of-function CARD11 mutant...

Read the full 241 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$35 USD
More Info >